ERBB2 and ovarian cancer: Early demonstrations of TAT to significantly prolong mouse survival using Bi-213- or At-211-immunoconjugates in peritoneal disease models (Bloechl et al., 2005; Elgqvist et al., 2006) were followed by successful TAT using Th-227-DOTA-p-benzyl-Trastuzumab in HER2-positive mouse ovarian cancer models (Heyerdahl et al., 2012).